Literature DB >> 6452474

Inhibition of T cell-mediated cytolysis by monoclonal antibodies directed against Lyt-2: heterogeneity of inhibition at the clonal level.

H R MacDonald, N Thiernesse, J C Cerottini.   

Abstract

The inhibitory effect of monoclonal anti-Lyt-2 antibodies on T cell-mediated cytolysis has been investigated at the clonal level. In agreement with previous reports from several laboratories, populations of cytolytic T lymphocytes (CTL) generated in vitro in mixed leukocyte cultures (MLC) were reversibly inhibited by monoclonal anti-Lyt-2 antibodies in a dose-dependent fashion. However, when alloimmune peritoneal exudate lymphocytes (PEL) were used as a source of CTL, little or no inhibitory effect of anti-Lyt-2 antibodies on cytolysis was observed. A series of CTL clones derived from MLC or PEL populations was also tested for inhibition of cytolysis by anti-Lyt-2 antibodies. In agreement with results obtained at the population level, most MLC-derived clones (81%) were strongly inhibited by the reagent, whereas few PEL clones (15%) were inhibited. Several of these clones were expanded and maintained in culture without loss of their "inhibition phenotype." Flow cytofluorometric analysis using the same monoclonal anti-Lyt-2 antibodies further revealed that both inhibited and uninhibited clones expressed comparable amounts of Lyt-2 antigen. These results provide direct evidence that inhibition of CTL by anti-Lyt-2 antibodies is heterogeneous at the clonal level. The possibility that this heterogeneity may be related to avidity of antigen receptors is discussed.

Mesh:

Substances:

Year:  1981        PMID: 6452474

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  The functional association of Lyt antigens with lymphokine production.

Authors:  N Hollander; J Shepshalovich
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

Review 2.  T-cell clones and T-cell receptors.

Authors:  F W Fitch
Journal:  Microbiol Rev       Date:  1986-03

3.  Control of immune interferon release by cytotoxic T-cell clones specific for influenza.

Authors:  P M Taylor; D C Wraith; B A Askonas
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

4.  Significance of Lyt phenotypes: Lyt2 antibodies block activities of T cells that recognize class 1 major histocompatibility complex antigens regardless of their function.

Authors:  S L Swain
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

5.  Comparative analysis of core amino acid residues of H-2D(b)-restricted cytotoxic T-lymphocyte recognition epitopes in simian virus 40 T antigen.

Authors:  A M Deckhut; J D Lippolis; S S Tevethia
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  Mouse Lyt-2 antigen: evidence for two heterodimers with a common subunit.

Authors:  G Jay; M A Palladino; G Khoury; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

7.  Modulation in vivo of Lyt 2 antigen expression on T cells by anti-Lyt 2 antibody: effects on Con A-induced unresponsiveness.

Authors:  T T MacDonald; C E Calkins; A L Rothermel
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

8.  Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response.

Authors:  M J Irwin; W R Heath; L A Sherman
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

9.  Induction of peripheral tolerance to class I major histocompatibility complex (MHC) alloantigens in adult mice: transfused class I MHC-incompatible splenocytes veto clonal responses of antigen-reactive Lyt-2+ T cells.

Authors:  K Heeg; H Wagner
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

10.  Clonal heterogeneity in the functional requirement for Lyt-2/3 molecules on cytolytic T lymphocytes: analysis by antibody blocking and selective trypsinization.

Authors:  H R MacDonald; A L Glasebrook; J C Cerottini
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.